Multiplex autoantibody profiling for autoimmune diseases and cancer
1 / 25

Multiplex autoantibody profiling for autoimmune diseases and cancer - PowerPoint PPT Presentation

  • Uploaded on

Multiplex autoantibody profiling for autoimmune diseases and cancer. April, 2, 2014. Profile antibodies to over 10,000 human proteins using Luminex xMAP™ technology. Jim Lazar, Ph.D. VP, Assay Development. OriGene Introduction. OTI Locations Rockville (HQTs/R&D) Seattle (Blue Heron)

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about ' Multiplex autoantibody profiling for autoimmune diseases and cancer' - kineta

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Multiplex autoantibody profiling for autoimmune diseases and cancer

Multiplex autoantibody profiling for autoimmune diseases and cancer

April, 2, 2014

Profile antibodies to over 10,000 human proteins using Luminex xMAP™ technology

Jim Lazar, Ph.D.

VP, Assay Development

Origene introduction
OriGene Introduction cancer

  • OTI Locations

    • Rockville (HQTs/R&D)

    • Seattle (Blue Heron)

    • Delaware (SDIX)

    • Maine (SDIX)

    • Foster City (BioCheck)

    • Beijing

    • Wuxi

Antibodies as biomarkers
Antibodies as Biomarkers cancer

  • The immune system functions as a an early warning system.

    • Malignant transformation, infections, and many diseases can trigger an immune response

  • Antibodies are abundant, easily detectable and stable in serum.

Autoantibodies to tumor antigens
Autoantibodies to Tumor Antigens cancer

  • Tumors typically over-express multiple normal and mutant antigens

  • Autoantibodies to tumor antigens can be detected much earlier than other cancer biomarkers

  • Frequency of autoantibody responses to an individual tumor antigen is typically 15-20%.

  • Responses to a panel of antigens can be higher than 90%

  • Multiplexed autoantibody detection to a panel of antigens is necessary.

What is EarlyCDT–Lung?

EarlyCDT-Lung is a simple, physician-ordered, diagnostic blood test that measures the presence of autoantibodies to a panel of seven lung cancer-associated antigens.

Autoimmune diseases
Autoimmune Diseases cancer

  • Autoimmune diseases affect an estimated 3% of the world population.

  • Over 150 recognized autoimmune diseases.

  • Each disease is characterized by autoantibodies to multiple antigens.

  • Profiles may help classify disease variants and indicate organ-specific involvement.

  • Autoantibody profiles may help guide the development of antigen-specific tolerizing therapy.

Biomarker discovery
Biomarker Discovery cancer

  • Proteomic /2D gel methods

  • Proteomic Mass Spec methods

  • High Density Protein Microarrays

Identification of many targets from a small number of samples

Biomarker Screening

& Quantitative Evaluation

Large sample #s

Refine target list

ROC calculations

  • Luminex Bead Arrays

  • Mid-Density Multiplexed methods

Clinical Assays

  • Luminex Bead Arrays

  • Low-Density Multiplexed methods

10 000 full length human proteins
10,000+ Full Length Human Proteins cancer

  • Produced from TrueORF Gold™ cDNA clones

    • Fully sequenced

    • Expression validated

  • Expressed in HEK293 cells

    • Human-expressed

    • Affinity purified

  • Native presentation

    • Optimal preservation of protein structure,

    • post-translational modifications

Available antigens
Available Antigens cancer

Any of OriGene’s >10,000 purified proteins can be custom-coupled to Luminex beads

Luminex xmap technology
Luminex xMAP™ technology cancer

  • Multiplex Bead Array

  • Efficient high-throughput microplate format

  • Up to 100 targets per well

  • OriGene is a Luminex partner and Certified Assay Developer

Assay principle
Assay Principle cancer


Protein-coupled Luminex Beads

Sample containing human IgG


Mix with Anti-human PE Conjugate

Read Signal in Luminex

Product configuration
Product Configuration cancer

  • TruePlex™ Human Antibody Profiling Kit

    • Assay Reagents, Control Bead Mix, Positive Control

combine with

  • Custom TruePlex™ Antibody Profiling Array

  • TruePlex™ Antibody Profiling Array

  • (pre-defined array)


Multiple profiling arrays can be mixed together and analyzed as a larger multiplex

Assay protocol
Assay Protocol cancer

Dilute sample

Mix with beads, incubate

Total time – about 2.5 hours for 96 samples

Up to 100 results per well

Quantitative results

Wash, add conj. & incubate


Read in Luminex

Analyze Data

Stringency options
Stringency Options cancer

  • Sample Diluent can be prepared at different stringencies

    • High, medium or low

  • High-stringency Sample Diluent will minimize non-specific signals and is recommended for initial sample testing.

  • The medium- or low-stringency Sample Diluent may give better results for samples

    • with low autoantibody levels,

    • in which the antibody affinity may be low

    • for higher sample dilutions (1:500 or greater),

Available cancer tumor antigens known to generate autoantibodies
Available cancer paneltumor antigens known to generate autoantibodies

  • Breast Cancer

    • ASB-9, BAT4, BDNF, Survivin, Livin, BMX, BRCA2, P16, CSNK1E, NY-ESO-1/LAGE1, CTBP1, DBT, EIF3E, HER2, Fibulin, FKBP4, GIPC-1, HSP-90, HSPA4, HSP-27, HSP-60, IMP1 , P62, IMP2, MUC1, C-Myb, c-myc, PDCD6IP, PPIA, PRDX2, RAB5A, RAC3, Lipophilin B, SERPINH1, SF3A1, SOX2, p53, TRIM32, UBAP1

  • ProstateCancer

    • Caldesmon 1, Clusterin, c-myc, HER2/neu, HSP70, HSP71, IMP1, MCP1, NY-ESO-1/LAGE1, p53, p62, p90, PARK7, PSA, RACE, SSX2, SSX4, Survivin, TARDBP, TTLL12

  • Pancreatic Cancer


  • Antigens for other cancers and diseases available including

    • Ovarian cancer, melanoma, hepatocellular carcinoma, lung cancer, diabetes, COPD, multiple sclerosis

Extensive bibliography available
Extensive Bibliography Available panel

Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma.E Piura and B PiuraJ Oncol, Jan 2011; 2011: 982425.

Seromic profiling of ovarian and pancreatic cancer.

S. Gnjatic S, et al.

PNAS U S A. Mar 2010 16;107(11):5088-93.

A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis

François Le Naour, et al.

Mol. Cell. Proteomics, Mar 2002; 1: 197 - 203.

Multiple serological biomarkers for colorectal cancer detection.

CC Chan, et al.

Int J Cancer, Apr 2010; 126(7): 1683-90.

Summary panel

  • Autoantibodies are useful biomarkers for cancer and autoimmune diseases.

  • OriGene’s TruePlex profiling kits are optimally suited for biomarker screening and validation.

  • Choose from over 10,000 proteins expressed in human cells.

  • The assay procedure is simple and fast.

  • Make great discoveries

  • Improve human health

Thank you for attending
Thank you for attending ! panel

Questions ?

Contact us:

[email protected]

[email protected]

240-620-0237 (direct)